Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acetaminophen warnings

This article was originally published in The Tan Sheet

Executive Summary

Current labeling of OTC acetaminophen products is adequate and an additional general allergy warning or one concerning cross-reactivity for aspirin-sensitive patients is not warranted, McNeil Consumer Healthcare states in comments to FDA. The comments are in response to a June 9 submission filed by Whitehall-Robins (marketer of the ibuprofen analgesic Advil) arguing acetaminophen has allergenic potential and should be required to carry warnings (1"The Tan Sheet" July 5, In Brief). In its response, McNeil cites four new studies and a chart showing a lower incidence of allergic adverse events related to acetaminophen use than with ibuprofen, naproxen sodium and other ingredients

Related Content

Topics

UsernamePublicRestriction

Register

PS090632

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel